Mirum Pharmaceuticals, Inc.
MIRMNasdaqCIK 1759425HealthcareFiscal year ends Dec 31
Reports and events: 149 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2616:47 ET | 8-K | 8.01 Other events | 0001759425-26-000054 |
| 2026-10-1308:09 ET | 8-K | 8.01 Other events | 0001759425-26-000051 |
| 2026-09-2808:02 ET | 8-K | 8.01 Other events | 0001759425-26-000049 |
| 2026-09-0808:34 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001759425-26-000047 |
| 2026-08-0516:06 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001759425-26-000045 |
| 2026-08-0516:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-26-000044 |
| 2026-06-1816:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-275811 |
| 2026-05-1816:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-228902 |
| 2026-05-0616:07 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001759425-26-000037 |
| 2026-05-0616:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-26-000036 |
| 2026-05-0408:00 ET | 8-K | 8.01 Other events | 0001193125-26-202609 |
| 2026-04-2708:07 ET | 8-K | 8.01 Other events | 0001193125-26-179048 |
| 2026-04-2316:39 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0001759425-26-000027 |
| 2026-04-0816:13 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001759425-26-000021 |
| 2026-02-2516:28 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001759425-26-000013 |
| 2026-02-2516:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-26-000010 |
| 2026-01-2716:12 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-26-000093 |
| 2026-01-2616:10 ET | 8-K | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-022582 |
| 2026-01-1208:40 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001759425-26-000004 |
| 2025-12-1916:06 ET | 8-K | 8.01 Other events | 0001193125-25-326822 |
| 2025-12-1908:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-325825 |
| 2025-12-0808:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-310611 |
| 2025-11-1716:52 ET | 8-K | 8.01 Other events | 0001759425-25-000057 |
| 2025-11-0417:26 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001231919-25-000420 |
| 2025-11-0416:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001759425-25-000054 |
| 2025-11-0416:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-25-000053 |
| 2025-08-2017:17 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001415889-25-022494 |
| 2025-08-0616:06 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001759425-25-000041 |
| 2025-08-0616:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-25-000040 |
| 2025-05-3016:35 ET | 8-K | 5.07 Shareholder vote results | 0001759425-25-000034 |
| 2025-05-0716:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001759425-25-000032 |
| 2025-05-0716:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-25-000030 |
| 2025-04-1416:06 ET | DEF 14A | Proxy statementPeriod 2025-04-14 | 0001759425-25-000022 |
| 2025-02-2616:09 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001759425-25-000014 |
| 2025-02-2616:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-25-000012 |
| 2025-01-1308:32 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001759425-25-000003 |
| 2024-11-1208:14 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001759425-24-000038 |
| 2024-11-1208:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-24-000037 |
| 2024-08-0716:11 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001759425-24-000031 |
| 2024-08-0716:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-24-000029 |
| 2024-06-1708:03 ET | 8-K | 8.01 Other events | 0001193125-24-162056 |
| 2024-06-0616:38 ET | 8-K | 5.07 Shareholder vote results | 0001759425-24-000023 |
| 2024-05-3117:24 ET | 8-K | 8.01 Other events | 0001193125-24-151965 |
| 2024-05-0816:16 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001759425-24-000019 |
| 2024-05-0816:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-24-000017 |
| 2024-04-2316:20 ET | DEF 14A | Proxy statementPeriod 2024-04-23 | 0001759425-24-000011 |
| 2024-03-1517:03 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-032289 |
| 2024-02-2816:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759425-24-000005 |
| 2024-01-1616:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-008569 |
| 2024-01-0808:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003965 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.